Wordt geladen...
Multi-center, randomized, double-blind, placebo-controlled, exploratory study to evaluate the efficacy and safety of HAD-B1 for dose-finding in EGFR positive and locally advanced or metastatic NSCLC subjects who need Afatinib therapy: Study protocol clinical trial (SPIRIT Compliant)
BACKGROUND: In recent studies, afatinib, a second-generation inhibitor, showed superior outcomes, when compared to the first-generation of EGFR-tyrosine kinase inhibitors (TKIs), such as erlotinib and gefitinib, in patients with advanced non-small cell lung cancer (NSCLC) harboring mutations of epid...
Bewaard in:
| Gepubliceerd in: | Medicine (Baltimore) |
|---|---|
| Hoofdauteurs: | , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Wolters Kluwer Health
2020
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7004641/ https://ncbi.nlm.nih.gov/pubmed/31977865 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/MD.0000000000018735 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|